drugset / Trial / NCT07462143

A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer

NCT07462143

Phase 2/3 Recruiting 80 enrolled RemeGen Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase Ⅱ/Ⅲ study. The purpose of this study is to evaluate the efficacy and safety of RC148 combined with chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (CRC)

Timeline

Start
2026-05-12
Primary completion
2027-05-12
Completion
2030-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RC148 Unknown
Background Capecitabine Small molecule
Background Oxaliplatin Small molecule

Indications